Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Uterine leiomyomas with an estimated incidence of 50%-80% are the most common tumors of female reproductive system. Statins as a HMG-CoA reductase inhibitors inhibit the mevalonate pathway of cholesterol synthesis, thus have been known as a group of drugs used for treatment of hypercholesterolemia. Statins inhibit proliferation of several cell types including vascular smooth muscle, hepatocytes and other cell types. Leiomyomas are benign uterine tumors characterized by smooth muscle proliferation and excessive deposition of extracellular matrix. In the present study we aim to evaluate the effect of simvastatin on uterine leiomyoma development and growth.
The proposal of the present study approved by our institutional review boards and institution's ethical committee, and all participants will sign a written consent before enter to study. All patients will be randomly divided into three groups and will be randomized to receive simvastatin 40 mg orally + vaginal placebo, simvastatin 40 mg vaginally + oral placebo and vaginal placebo + oral placebo for 3 months.
CBC, Lipid profile, kidney & Liver function tests, FBS & hormonal evaluation will be performed before and after the treatment. Ultrasound examination will be performed before and after the treatment for determining of the number, size, and site of the myoma and also size of the uterus.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Simvastatin and vaginal placebo | Experimental | The patients with leiomyoma receive simvastatin 40 mg orally+ vaginal placebo will be given every day for 3 months. |
|
| Simvastatin and oral placebo | Experimental | The patients with leiomyoma receive simvastatin 40 mg orally+ oral placebo will be given every day for 3 months. |
|
| Vaginal placebo+ oral placebo | Experimental | The patients with leiomyoma receive Vaginal placebo+ oral placebo every day for 3 months. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| oral drug and vaginal placebo | Drug | prescription of simvastatin 40 mg orally+ vaginal placebo every day for 3 months. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Uterine fibroid size | Evaluation the size of Uterine fibroid withultrasound. | 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Uterine size | Evaluation the uterine size with ultrasound. | 3months |
| Plasma concentration of Vitamin D3 | Evaluation the Plasma concentration of Vitamin D3 with blood sampling. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Nasser Aghdami, MD,PhD | Contact | (+98)23562000 | 516 | nasser.aghdami@royaninstitute.org |
| Leila Arab, MD | Contact | (+98)23562000 | 414 |
| Name | Affiliation | Role |
|---|---|---|
| Mahnaz Ashrafi, MD | ) Endocrinology and Female Infertility Department, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran | Study Director |
| Hamid Gourabi, PhD | Head of Royan Institute | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Royan Institute | Recruiting | Tehrān | Iran |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D007246 | Infertility |
| ID | Term |
|---|---|
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D004364 | Pharmaceutical Preparations |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| oral drug and oral placebo | Drug | prescription of simvastatin 40 mg orally+ oral placebo every day for 3 months. |
|
| Vaginal placebo+ oral placebo | Drug | prescription of Vaginal placebo + oral placebo every day for 3 months. |
|
| 3 months |
| Firoozeh Ahmadi, MD | ) Endocrinology and Female Infertility Department, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran | Study Director |
| Nadia Jahangiri, MSc | ) Endocrinology and Female Infertility Department, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran | Principal Investigator |